

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A stakeholder raised, as considered in other NICE appraisals for metastatic prostate cancer, older people are more likely to be unsuitable to receive taxane chemotherapy. If chemotherapy is therefore an eligibility requirement for Lu-PSMA-617, there is the risk of indirect discrimination based on age as older people would be prevented from accessing this treatment.

A stakeholder raised there are a limited number of clinical centres would be able to assess patients for PSMA positivity using PET/CT scanning and deliver 177Lu-PSMA-617. This may result in inequality due to the need for some patients to travel long distances to receive treatment. This is not considered to be an equality issue but access to treatment and services is expected to be discussed during the appraisal.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

With regards to age potentially affecting suitability for prior taxanes, the committee will be required to consider the technology according to its marketing authorisation. Equality issues will be presented to the committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director: Janet Robertson

Date: 03/11/2021